Ultrasound RF Data for Discriminating Between Benign and Malignant Ovarian Masses
NCT ID: NCT06473766
Last Updated: 2025-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2024-07-15
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
According to IOTA terminology, 13% of ovarian masses detected on ultrasound examination are classified as solid. Solid ovarian masses have a risk of malignancy of 60%-75%2 and the discrimination between benign and malignant in this morphological category is challenging. Additionally, it has been estimated that 30% (25/84; 95% CI 18 to 44%) of solid malignant ovarian masses are metastases from non-ovarian tumors. The discrimination between primary ovarian cancer and metastatic tumors in the ovary is also clinically important for planning adequate therapeutic procedures. It is worth exploring the predictive performance of the diagnostic tools in identifying ovarian masses with ultrasound solid morphology.
Preliminary data (unpublished) on radiomics analysis and ovarian masses provided that benign and malignant ovarian masses with solid morphology have different radiomics features in a monocentric retrospective study. However, no statistically significant differences have been observed between primary ovarian cancer and metastases to the ovary.
A new technology is emerging in engineering ultrasound field: the analysis of ultrasound summed RF data- raw data generated by the interface of ultrasound beams with human tissues. To date, raw data are not utilized for conventional imaging and their eventual role in clinical practice is unknown. Indeed, summed RF data could better correlate with biological parameters then parameters identifiable in B-mode images. Summed RF data could also improve radiomic analysis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prediction of Ovarian Malignancy in the Presence of Sonographic Pelvic Mass
NCT01477788
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
NCT04178018
The Use of HE4 With Simple Ultrasound Rules to Predict Malignancy in a Pelvic Mass
NCT03982914
Transvaginal Ultrasound and Photoacoustic Imaging of the Ovary
NCT03262818
The Application of Sentinel Lymph Node Mapping Technique in the Surgery of Early Epithelial Ovarian Cancer
NCT06673511
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Feasibility of RF data to compare RF data in ovarian masses
To evaluate the feasibility of RF data in patients with ovarian masses with solid ultrasound morphology
1. To compare RF data in benign and malignant ovarian masses with ultrasound solid morphology. Histology will be the reference standard.
2. To compare RF data in primary invasive and metastases to the ovary.
3. To describe the reliability of RF data between different images of the same solid ovarian tumor.
RF data extraction
To will be acquired:
10 S-Harmonic images (5 in longitudinal plane, 5 in orthogonal plane), 10 B-mode fundamental images (without Harmonic), 1 gray-scale video clip, 1 gray-scale 3D vol will be stored in Harmonic settings and RF-preset.
The Region of interest (ROI) of each image will be manually segmented by a trained gynecologist using the software Aliza version 1.48. The ROI will include only the solid component of the mass. Additional analysis will be performed by using a predefined ROI (area 2x2 cm2). Radiomic features will be extracted using the MODDICOM, an open-source in-house software solution developed by the Knowledge Based Oncology Labs (Rome, Italy) for quantitative imaging analysis fully compliant with the Image Biomarker Standardization Initiative recommendations. The features will be considered: intensity-based statistical and textural.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RF data extraction
To will be acquired:
10 S-Harmonic images (5 in longitudinal plane, 5 in orthogonal plane), 10 B-mode fundamental images (without Harmonic), 1 gray-scale video clip, 1 gray-scale 3D vol will be stored in Harmonic settings and RF-preset.
The Region of interest (ROI) of each image will be manually segmented by a trained gynecologist using the software Aliza version 1.48. The ROI will include only the solid component of the mass. Additional analysis will be performed by using a predefined ROI (area 2x2 cm2). Radiomic features will be extracted using the MODDICOM, an open-source in-house software solution developed by the Knowledge Based Oncology Labs (Rome, Italy) for quantitative imaging analysis fully compliant with the Image Biomarker Standardization Initiative recommendations. The features will be considered: intensity-based statistical and textural.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients who will undergo surgery within 120 days after the ultrasound examination.
3. Patients at least 18 years old.
4. Informed consent signed.
Exclusion Criteria
2. Patient refusal
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medison
INDUSTRY
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Testa Antonia Carla
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antonia Carla Testa, Professor
Role: PRINCIPAL_INVESTIGATOR
Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6267
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.